BLOG

Scrip_Domain

CTAD 2023: Grifols/Araclon Ponder Next Steps For ABvac40 After Phase II Readout

The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.